Amycretin
GLP-1 and amylin agonism combined in a single molecule, not a two-drug combination.
Identity
- Class
- Unimolecular GLP-1 + amylin receptor agonist (peptide)
- Source
- Synthetic; engineered unimolecular dual agonist
- Receptor
- GLP-1 receptor + amylin receptors
Mechanism
Amycretin is a single molecule that agonizes both the GLP-1 receptor and amylin receptors — two appetite-suppressing pathways combined in one agent rather than as a two-drug combination. Developed in both subcutaneous and oral forms, it is an early-stage attempt to capture the additive GLP-1-plus-amylin effect from a single molecule. It is investigational.
Reference notes
- Combines GLP-1 and amylin agonism in one molecule — the single-agent counterpart to the CagriSema combination.
- Under investigation in both injectable and oral formulations.
- Investigational and early-stage — first-in-human and phase 1b/2a data only.
Selected literature
Curated peer-reviewed reviews, sourced from PubMed. Selected for relevance, not exhaustive — open any entry on PubMed for the full record and its primary citations.
- 1.Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trial · Lancet (London, England), 2025 · PMID 40550229
- 2.Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study · Lancet (London, England), 2025 · PMID 40550231